Special Reports:

Our HIV reporting of the past decade

< Back to special reports

A large chunk of our reporting focuses on HIV. Since the launch of Bhekisisa in 2013, we’ve covered HIV in-depth — from the impact of the virus on former president Nelson Mandela’s family to the advances in antiretroviral treatment and anti-HIV pills and injections. We’ve also looked at the impact of inequality and discrimination on the spread of HIV, the link between gender-based violence and HIV — and ways to fix it.

HomeMultimedia #Aids2020 study: Dolutegravir doesn't pose a higher risk for birth defects....

[WATCH] #Aids2020 study: Dolutegravir doesn’t pose a higher risk for birth defects. Here’s why

Dolutegravir is part of a three-in-one pill, and unlike other ARVs, can be taken on an empty stomach. Previously, it was thought to hold a risk of birth defects to babies when mothers with HIV fell pregnant while using the drug or used it during the early stages of pregnancy.

Laura Lopez Gonzalez is a freelance health journalist and editor. She was Bhekisisa's news editor then deputy editor between 2016 and 2020.

Dylan Bush was a health journalist at Bhekisisa from February 2016 to September 2023.